|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
Datamonitor, April 2008, Pages: 205
As the reimbursement status for the cost of hospital-acquired infections is under pressure by payors, interest in preventing these complications at the outset is growing. Nosocomial vaccines offer one route of prevention. This report assesses the clinical pipeline candidates five key nosocomial pathogens and their potential market environment including target population size estimates.
Scope:
- In-depth analysis of epidemiology, spread, costs and reimbursement linked to nosocomial infections across the major Western markets
- Thorough general and pathogen-specific assessment of the market potential for the major 5 classes of nosocomial vaccines
- In-depth discussion and sizing estimates of potential target groups for nosocomial vaccines by pathogen
- Review of alternative strategies for infection prevention and comparison with vaccination
Report Highlights:
The increasing incidence and severity of nosocomial infections has sparked an interest in preventive strategies such as vaccination. High costs and reimbursement cuts associated with nosocomial infections provide a strong incentive for healthcare stakeholders to invest in infection prevention, providing a strong rationale for vaccine development.
In the highly cost-conscious nosocomials market, a prudent definition of vaccination target groups will be crucial to satisfy the stringent cost-benefit analysis. Whereas patients undergoing planned hospital stays will benefit from vaccination, alternative prevention methods may be preferable for immuno-compromised, newborn and acute patients.
It is believed that C. difficile vaccines will have the easiest route to market due to the large and well-defined target population and a high unmet need. Vaccines against S. aureus and P. aeruginosa could prove valuable in selected target groups, whereas there is only a limited potential for vaccines against S. epidermidis and enterococcus.
Reasons to Purchase:
- Review the epidemiological, clinical and economical factors driving new product decisions in nosocomial vaccine development.
- Gain insight into the pipeline through a discussion of key candidates in clinical development for five nosocomial pathogens.
- Understand and identify key market opportunities by reviewing sizing estimates for key target populations by pathogen.
Customers who bought this item also bought
Stakeholder Opinions: Nosocomial Infections - The Need for New Gram-negative Drugs
Commercial Perspectives: Vaccines - Nosocomial Pathogens
Stakeholder Opinions: Skin and Soft Tissue Infections
Urinary Tract Infections: Growing Resistance Rates bring Opportunities for Both New and Old Drugs
Infection Control in Ambulatory Care 2009 Update
Stakeholder Opinions: Biologics in Infectious Diseases - Well Defined Target Populations are Key to Commercial Success
Sexually Transmitted Infections - The Silent Menace
Bacterial Infections: An Epidemiological Overview
Bacterial Infections: An Epidemiological Overview
Pipeline Perspectives: Vaccines - Expanding Portfolio Diversity
Competitor Analysis: Immunotherapy of S. aureus Infections
Infections - Herpes Simplex Virus Infection Drug Pipeline Report
|
|
|
|
